On May 2, 2024 Alpha-9 Oncology (Alpha-9), a clinical stage company developing radiopharmaceuticals for the treatment of cancer patients worldwide, reported that the first participant has been dosed in the Phase 1 study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor (MC1R) for the imaging of locally advanced or metastatic melanoma (Press release, Alpha9 Oncology, MAY 2, 2024, View Source [SID1234642574]). MC1R expression is known to be elevated in malignant melanoma and other types of skin cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 multi-centre study is evaluating the tumour uptake and normal tissue distribution of 68Ga-A9-3202 in participants with locally advanced or metastatic melanoma (ACTRN12624000085572). This new agent, in conjunction with current standard CT or PET/CT imaging, will be used in the future to identify patients suitable to receive a novel radiotherapeutic agent targeting MC1R also developed by Alpha-9.

"This agent is the first step in our effort to develop radiopharmaceuticals targeting MC1R for the treatment of patients with advanced or metastatic melanoma," commented Dr. Ovid Trifan, Chief Medical Officer at Alpha-9. "We’re excited to advance our portfolio of molecules further into the clinic."